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A B S T R A C T
Purpose: A paper, published a decade ago, endorsed doctors’ right to avoid discussing Sudden
Unexpected Death in Epilepsy (SUDEP). It did not negate discussion, advocating same where appropriate.
This paper investigates the current situation to identify any changes.
Methods: The tort of negligence includes a duty to discuss ‘‘material risks’’ and adhere to accepted
practice. Within the last decade, ‘‘material risks’’ for SUDEP have not altered signiﬁcantly and
international practice discusses SUDEP with those patients who seek advice or in whom such discussion
is designed to improve patient compliance.
Results: Doctors are unlikely to be found negligent for not discussing SUDEP, acknowledging a push
encouraging same, despite it being contrary to routine practice in the US, Italy, UK and elsewhere.
Doctors should continue to practice the ‘‘art of medicine’’, discuss SUDEP when warranted and with
patients seeking such advice. They must warn about risks, such as bathing alone, avoiding accident and
injuries and possibly SUDEP in non-compliant patients and also consider the impact of such discussion.
With no ‘material’ changes in the last decade, doctors must recognise when to discuss SUDEP, with which
patients and in what context, accepting it may have a negative psychosocial impact on family dynamics
unless discussed in a culturally competent fashion, to avoid causing additional stress for families where
accepting the diagnosis of epilepsy may already prove difﬁcult.
Conclusion: Having formed a therapeutic relationship with the patient, discussion of SUDEP should be
considered within that context, acknowledging the ‘‘art of medicine’’ and the implications of such
discussion, similar to the situation a decade ago.
 2015 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
Contents lists available at ScienceDirect
Seizure
jou r nal h o mep age: w ww.els evier . co m/lo c ate /ys eiz1. Introduction
Consequent to a review of the observations of an outpatient
clinic’s experience with Sudden Unexplained Death in Epilepsy
(SUDEP), more than a decade ago, the hypothesis was proffered
that there were no ‘material risks’, associated with SUDEP, to
categorically mandate its discussion with every patient with
epilepsy, irrespective of any other considerations [1]. A ‘material
risk’ is a legal term, which forms part of the overarching duty of
care that a clinician owes to his/her patient.
The deﬁnition of a ‘material risk’ was set out in the seminal
Australian case of Rogers v Whittaker and stated that it was
‘‘. . .material if it is a risk to which a reasonable person in the position of
the patient would be likely to attach signiﬁcance, or it is a risk to which* Correspondence to: Suite 5, Level 6, 12 Thomas Street, Chatswood, NSW 2067,
Australia. Tel.: +61 02 9415 3800; fax: +61 02 9413 1353.
E-mail address: roy.beran@unsw.edu.au
http://dx.doi.org/10.1016/j.seizure.2015.02.009
1059-1311/ 2015 British Epilepsy Association. Published by Elsevier Ltd. All rights rethe medical practitioner knows or ought reasonably to know the
particular patient would be likely to attach signiﬁcance in choosing
whether or not to undergo a proposed treatment. . .’’ [2]. It follows
that a doctor, treating a patient with epilepsy, owes his/her patient
a duty to advise or inform that patient of those facts which, it is
expected, would directly impact on that patient’s decision to
accept, or reject, a proposed treatment. Rogers v Whittaker [2]
departed considerably from the Bolam Principle, which was
established in an English case and stated that ‘‘. . .the test is the
standard of the ordinary skilled man exercising or professing to have
that special skill . . .in the case of a medical man, negligence means
failure to act in accordance with the standards of reasonably
competent medical men at the time. . .’’ [3].
The legal pendulum has swung to and fro, regarding the
accepted legal expectations of that which the clinician must
discuss with his/her patients but the need to explain ‘material
risks’ has been widely accepted. It follows that if it can be
established that there are ‘material risks’ associated with SUDEP
then these need to be discussed with patients who have epilepsy.served.
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Liability Act, 2002 [4], which incorporated a number of consider-
ations including:
- A professional does not incur liability re negligence if acting in a
manner widely accepted by peer professionals;
- Such reliance is negated if the Court considers that the opinion
relied upon is irrational;
- There may be more than a single professional opinion which does
not preclude any or all being accepted; and
- Peer professional opinion does not necessitate universal accep-
tance to constitute wide acceptance [4].
What was set out in the clinic’s experience of SUDEP [1] was
that it could not establish any clear cut ‘material risks’, knowledge
of which would directly inﬂuence a patient’s willingness to accept,
or reject, proposed treatment. This in no way negates the increased
risk of premature mortality associated with a diagnosis of epilepsy
[5] nor the fact that SUDEP represents the most common cause of
death, as a direct consequence of having epilepsy [6], but it negates
an absolute requirement to discuss SUDEP unless information is
sought.
It has now been a decade since that assessment was published
[1] and the basic considerations, encapsulated in an understanding
of both ‘material risks’ and the application of a consensus
approach, as broadly outlined in both the Bolam Principle [3]
and reinforced in the Civil Liability Act [4], deserve to be revisited.
What follows is an analysis of these two considerations, which
underpin both the legal and ethical obligations that a clinician
owes to his/her patients with epilepsy.
2. Material risks
Since the publication of the clinic’s experience [1] there have
been a number of attempts to further delineate the risks of SUDEP
[6–12] and it is fundamental to the consideration of ‘material risk’
to review these ﬁndings. There is debate that SUDEP may be a peri-
ictal phenomenon [6] with a number of papers attesting to same
[13] but only 2/3 of cases demonstrated evidence of preceding
seizure [13]. Polytherapy, relying on more than a single antiepi-
leptic medication, has been postulated as a risk factor for SUDEP
[1,12] but may not be an independent risk factor and may simply
represent more refractory epilepsy [7], which could suggest
increased seizures as the pivotal factor. Untreated epilepsy, with
associated seizures, is also a risk factor [7]. Both might suggest
seizures themselves reﬂect causative factors, as polypharmacy is a
direct consequence of failure to control with monotherapy and
hence indicative of increased seizure frequency. As most SUDEP
occurs in sleep, the use of monitoring devices or nocturnal
supervision has been advocated to decrease risk [7].
There has emerged growing evidence to support possible
genetic predisposition to SUDEP [8,9,10,11]. Hitiris et al. [14]
identiﬁed respiratory arrest, cardiac dysrhythmia or asystole as the
probable ﬁnal common mechanism for SUDEP and these have been
linked to genetic factors, particularly those associated with
prolonged QT syndrome [8,9]. People with prolonged QT may
present with seizures as the initial presenting feature [14] and it is
postulated that SCN1A, SCN1B and SCN5A (genes encoding for the
sodium channels) and KCNQ1, KCNQ2, KCNQ3 and KCNH2 (genes
encoding for the potassium channels) may be implicated both in
SUDEP and long QT syndrome (LQTS) but it is far too early to be
categorical about the association [9]. The SCNSA mutation has been
found in SUDEP with idiopathic epilepsy [10] and the SCNIA
mutation has been identiﬁed in patients with GEFS+ [8] and SUDEP
with Dravet Syndrome [11]. Only time will tell if there is really a
genetic predisposition to SUDEP but that would then need to befurther explored to determine if this can translate into a form of
intervention to prevent SUDEP occurring. The ﬁrst step is to
establish that the genetic predisposition exists and is not a
coincidental ﬁnding.
Despite the attempts to identify unequivocal risk factors for
SUDEP [1,6,7,8,9], the ﬁndings have been conﬂicted, except for:
young age; refractory epilepsy; early onset; convulsive seizures;
male gender; and being in bed at the time of the SUDEP
[12,13,14,15,16]. The ILAE Commission on Epidemiology; Sub-
commission on Mortality has added to this list to include use of
lamotrigine as presenting higher risk, especially in those with
idiopathic generalised epilepsy but retracted that assertion when
reanalyzing the data [12], indicating that no particular anti-
epileptic medication was associated with increased risk of SUDEP.
The Subcommission concluded that it was the number of
convulsive seizures rather than the type of medication which
accounted for the increased risk of SUDEP [12].
What these data indicate is that there remain no absolute
‘material risks’ attached to SUDEP which would unequivocally
inﬂuence a patient’s willingness or otherwise, to accept a
treatment option. Poorly controlled epilepsy does carry with it
an increased risk of SUDEP and fear of SUDEP, in such cases, may
enhance patient compliance and an acceptance of the need to
adhere to medical advice. It is axiomatic that patients attending a
clinician, for the management of epilepsy, should be encouraged to
follow the prescribed treatment and use of the discussion of SUDEP
may offer an additional inducement. Having said same, there may
be a cultural divide in which parents may bring their child for
treatment yet still refuse anti-epileptic medications despite
discussion of SUDEP [17,18]. It follows that illness process and
treatment must be addressed in a culturally competent manner,
being aware of competing inﬂuences.
3. Application of Bolam Principle
Since the publication of the ﬁndings of the outpatient study of
SUDEP [1], there has been considerable debate regarding when and
whom to tell about it [5,19–27]. It remains controversial as to
whether all patients should be told and when [19,20,24–29]. The
actual telling about SUDEP may have negative consequences [1,28]
causing psychological effects and even provoking non-epileptic
seizures [28].
The National Institute for Clinical Experience (NICE) [21] and
the Scottish Intercollegiate Guidelines Network (SIGN) [22] both
advocate provision of adequate SUDEP information to patients and
their families. Some inconsistencies emerge from America where
the taskforce of the Epilepsy Society and Foundation advocates
disclosure re SUDEP [30] while the American Academy of
Neurology [31] has avoided its inclusion within quality assurance
for epilepsy [32]. In practice, only a minority of neurologists (5%)
discuss SUDEP with all their patients [26–28] and most are
selective with whom they discuss it. A third of US neurologists
never discuss SUDEP with a similar proportion restricting
discussion to those at increased risk [32]. Similar statistics applied
to Italian neurologists, of whom almost 2/3 restricted discussion to
selected more at risk patients [27]. When analysing patients
records, 4.06% (14/345) had documented discussion of SUDEP [26]
and the legal maxim is that if it is not documented, it did not
happen.
On the basis of these data, it would appear that the majority of
specialists who treat epilepsy do not routinely discuss SUDEP with
their patients but do so if, and when, they perceive a need for
providing additional information, especially for those patients at
increased risk. This would appear at odds with some guidelines and
with what some researches report to be patient expectation [21–
25,30].
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who do not routinely discuss SUDEP with all patients with
epilepsy. These same clinicians are acting ‘‘. . .in a manner widely
accepted by peer professionals; the opinion relied upon is (not)
irrational; and does not necessitate universal acceptance . . .’’ as per
the Civil Liability Act/s. Thus it seems established that selective
discussion of SUDEP with those patients, considered at risk,
complies with both the principles of the Bolam case and with
subsequent legislated Australian standards to avoid liability in
negligence.
The question arises whether neurologists, with a special
interest in epilepsy, are more likely to discuss SUDEP when
compared to general neurologists. This issue was speciﬁcally
addressed by Xu et al. who surveyed more than 100 patients
attending a tertiary referral hospital epilepsy clinic, over a period
of one year, of whom only 14% were properly informed about the
potential of SUDEP and of them the majority had obtained their
information from either the Internet or popular press, rather than
from their treating neurologist, despite it being a tertiary referral
epilepsy service. The role of the epilepsy nurse specialist or
advanced nurse practitioner, in possible discussion of SUDEP, has
also attracted attention but this was not provided within the study
by Xu et al. [33]. Involvement of such specialised nursing personnel
would be predicated by (a) previous discussion of SUDEP by the
attending physician, something that does not appear to be
routinely practised in other than selected cases and (b) access
to such specialised nursing staff who, more likely than not, would
not be available to community-based clinicians where the majority
of epilepsy is treated.
Access to SUDEP Action ( https://www.sudep.org/inquiries-
individualdeaths; accessed 06/02/2015) identiﬁed ‘‘Inquiries into
individual deaths’’ – exploring Coroners’ rulings on avoidable
epilepsy-related deaths‘‘. This identiﬁed 12 deaths of which one was
thought to be SUDEP related, in a 35 year-old male in whom medical
management was inadequate, in residential care, and was unrelated
to discussion of SUDEP. It also identiﬁed the 2011 Inquiry into the
deaths of Erin Casey and Christina Ilia and the earlier inquiry into
Colette Findlay.
Erin Casey was 19 when she died, with sub-therapeutic blood
levels of carbamazepine and poor adherence to her prescribed
regimen. She failed to appreciate the seriousness of her epilepsy
and lack of discussion of SUDEP resulted in complaint to the
Scottish Public Service Ombudsman. Christina Ilia, with asthma
and focal epilepsy, was 15 years at the time of her death. There was
evidence of a seizure, with clenched ﬁsts, but SUDEP was noted on
the death certiﬁcate.
In the analysis of risk factors for SUDEP, the coroner identiﬁed:
ongoing convulsive seizures; young age; poor seizure control;
learning disability; seizures during sleep; unwitnessed seizures;
and non-adherence to medical regimen, all of which are relevant to
poorly managed epilepsy. The coroner acknowledged that ‘‘. . . The
risk of SUDEP cannot be entirely eliminated. . .’’, thereby raising
questions of ‘‘material risk’’. It was accepted that triggers for
seizures were also triggers for SUDEP and these existed irrespec-
tive of SUDEP, thereby justifying discussion, especially ‘‘lifestyle’’
issues. The coroner commented on nocturnal supervision of people
with epilepsy and favoured use of nocturnal apnoea alarms,
despite expert witnesses testifying that adherence with these
devices was doubtful. As an accredited sleep physician, even with
patients who have unequivocal sleep apnoea, it is often difﬁcult to
achieve compliance with continuous positive air pressure, which is
a proven therapeutic intervention.
In both cases, the involved clinicians claimed failure to discuss
SUDEP as a consequence of potential ‘‘distress’’. This is a clinical
decision, based on the understanding of the prevailing doctor–
patient relationship, which is directly inﬂuenced by the conditionsat the time. In both cases, it is highly unlikely that these young
people would have complied with nocturnal alarms, thereby
making discussion thereof unlikely to change the risk factors.
Especially in student accommodation, it is unlikely that the
response to such alarm would have been adequate, thereby further
suggesting that such discussion would have been ‘immaterial’. The
coroner stated, ‘‘. . . Discretion must be left with the medical
profession. . . There may well be families . . . where such a
discussion would do more harm than good. . .’’. The coroner was
selective about what evidence to favour and ignored some
literature [26–29] which indicated that SUDEP was discussed on
a case-by-case basis and far from universally by treating
neurologists.
It is easy to be critical post hoc, once SUDEP, a truly tragic
situation, has occurred, following which the blame game will
emerge. In the decade, since the review of the ‘‘legal obligations’’ to
discuss SUDEP [1], both the application of material risks and Bolam
has not changed greatly. It remains that, even in specialised
epilepsy services, SUDEP is discussed with a minority of patients
[33]. Where compliance is an issue, as was the case with Erin Casey,
discussion of SUDEP may enhance adherence but equally the
monitoring of blood levels of antiepileptic medications may be
more effective and potentially more tangible to a teenager, with
discussion of therapeutic windows and concrete evidence of non-
compliance [34].
4. Discussion
At the time of publishing the ﬁndings of a single outpatient
epilepsy clinic’s experience with SUDEP, and its deliberations
concerning discussions with patients [1], an ensuing debate
emerged. This centred on the need to discuss SUDEP with all
patients and was largely motivated by patient advocacy [23–25].
At the time of initial presentation, review of ‘material risks’,
discussion of which would inﬂuence patient acceptance of
treatment, was considered fundamental to the legal obligation
to discuss SUDEP but there did not appear any such ‘material risks’
associated with SUDEP to mandate such discussion.
After a decade of endeavour, it would appear that the same
fundamental risk factors have not changed greatly and the
majority, with the exclusion of possible nocturnal monitoring
[7], cannot be modiﬁed other than to improve seizure management
and compliance. There has emerged a suggestion of a genetic
predisposition to SUDEP but this is far from conﬁrmed [8,9] and
again, at least at this stage, cannot be modiﬁed and therefore does
not constitute a ‘material risk’, which may result from treatment
being offered. On this basis, the situation has not changed
signiﬁcantly in the last decade and there remains no ‘material
risk’ that could be identiﬁed to demonstrate a failure of duty of
care, if SUDEP is not discussed with all patients who have epilepsy.
Similarly, the application of the Bolam Principle, namely that
few neurologists, irrespective of nationality, be it English,
American or Italian, discuss SUDEP with all of their patients with
epilepsy supports the approach of selective discussion. This does
not preclude such discussion but rather leaves latitude to discuss it
with those patients in whom such discussion may beneﬁt the
patient.
A patient has an indisputable right to receive honest and
comprehensive answers to questions asked of their doctor. This
includes questions related to SUDEP and where a patient seeks
such information the doctor has a duty of care to openly discuss
SUDEP to the best of that doctor’s knowledge and unequivocally
‘‘. . .in accordance with the standards of reasonably competent
medical men at the time. . .’’ [3]. It is unlikely that anyone, involved
in this debate, would argue this point and thus further discussion
concerning response to direct questioning is unwarranted. As the
R.G. Beran / Seizure 27 (2015) 47–5050times have changed and there is greater exposure to information it
is anticipated that more patients will ask, and be advised, about
SUDEP.
Where the questions are not asked is where the difference of
opinion arises. The data suggest that, in general, doctors do discuss
SUDEP with patients who are at increased risk [19,20,24,27,28]. This
is done as fear of SUDEP may provide a ‘material risk’ to encourage
patients to be more compliant and adhere to medical advice. While
fear of discussing SUDEP has been proffered as a reason for avoiding
such discussion, to avert potential psychological consequences
[1,28], where such discussion outweighs the risks to the patient, it
appears clinicians are using SUDEP as a tool to improve patient
protection. Culturally competent discussion of SUDEP, with patients
who are non-adherent to prescribed treatment, may address the
potential negative psychosocial impact of such discussion.
Just as no two patients are the same, no two patients present the
identical management problems. It follows that there should not
be a dogma which dictates that every patient should be treated
identically. As set out in the discussion of ‘material risk’, discussion
with a patient should comply with patient wishes and needs and
these will vary between patients. What should not vary is the
doctor’s goal of being responsive to the patient’s needs and to be
prepared to discuss those issues, including SUDEP, which the
patient needs to discuss, either to allay fears, to be simply better
informed or to facilitate better adherence to treatment. Where
such discussion has occurred this also should be documented
within the patient’s medical records to conﬁrm that such
discussion has occurred. Rather than being paternalistic, this is
responsive medicine that is patient speciﬁc and will answer
questions when raised or raise issues considered necessary to
improve that patient’s well being. This is the epitome of the ‘art of
medicine’ that must always focus on the individual patient and
that patient’s needs, thereby acknowledging the established duty
of care.
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